Thioglycoside antithrombotic agents

Drugs of the Future

Volumn 24, Issue 11, 1999, Pages 1241-1248

  Szabó, Gabriella ^a   Bozó, Éva ^a   Barabás, Éva ^a   Kedves, Rita ^a   Csomor, Katalin ^a,b   Kuszmann, János ^a  

^a Institute for Drug Research Budapest   (Hungary)

^b GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CHONDROITIN SULFATE; GYKI 39484; GYKI 39521; GYKI 39541; HEPARAN SULFATE; NAROPARCIL; THIOGLYCOSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0033369384     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.11.560611     Document Type: Review

References (39)

1. Ofosu, F.A., Gray, E. Mechanism of action of heparin: Application to the development of derivatives of heparins and heparinoids with antithrombotic properties. Semin Thromb Haemost 1988, 14: 9-17.
2. Walenga, J.M., Jeske, W.P., Bara, L. et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997, 86: 1-36.
3. Messmore, H.L. Jr. Heparin induced thrombocytopenia. 13th Meet Int Soc Haematol (Sept 3-8, Istanbul) 1995, Lectures 218-20.
4. Teien, A.N., Abildgaard, U., Höök, M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976, 8: 859-67.
5. Long, W.F. The anticoagulant activity of dermatan sulfate. Thromb Res 1988, 18: 493-503.
6. Okayama, M., Kimata, K., Suzuki, S. The influence of p-nitrophenyl β-D-xyloside on the synthesis of proteochondroitin sulfate by slices of embryonic chick cartilage. J Biochem 1973, 74: 1069-73.
7. Schwartz, N.B., Galligani, L., Ho, P-L., Dorfman, A. Stimulation of synthesis of free chondroitin sulfate chains by β-D-xylosides in cultured cells. Proc Natl Acad Sci USA 1974, 71: 4047-51.
8. Schwartz, N.B. Regulation of chondroitin sulfate synthesis. J Biol Chem 1977, 252: 6316-21.
9. Lugemwa, F.N., Esko, J.D. Estradiol β-D-xyloside, an efficient primer for heparan sulfate biosynthesis. J Biol Chem 1991, 266: 6674-7.
10. Fritz, T.A., Lugemwa, F.N., Sarkar, A.K. et al. Biosynthesis of heparan sulfate on β-D-xylosides depends on aglycon structure. J Biol Chem 1994, 269: 300-7.
11. Fritz, T.A., Agrawal, P.K., Esko, J.D. et al. Partial purification and substrate specificity of heparan sulfate α-N-acetylglucosaminiltransferase. Glycobiology 1997, 7: 587-95.
12. Bellamy, F., Horton, D., Millet, J. et al. Glycosylated derivatives of benzophenone, benzhydrol, and benzhydril as potential venous antithrombotic agents. J Med Chem 1993, 36: 898-903.
13. Millet, J., Theveniaux, J., Brown, N.L. The venous antithrombotic effect of LF-1351 in the rat following oral administration. Thromb Haemost 1992, 67: 176-9.
14. Witczak, Z.J. Thiosugars: Biological relevance as potential new therapeutics. Curr Med Chem 1999, 6: 165-78.
15. Bellamy, F., Barberousse, V., Martinet, L. et al. Thioxyloside derivatives as orally active venous antithrombotics. Eur J Med Chem 1995, 30 (Suppl.): 101-15.
16. Masson, P.J., Coup, D., Millet, J. et al. The effect of the β-D-xyloside naroparcil on circulating plasma glycosaminoglycans. J Biol Chem 1995, 270: 2662-8.
17. Bajusz, S., Szell, E., Bagdy, D. et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990, 33: 1729-35.
18. Jackson, C.V., Satterwhite J., Roberts, E. Preclinical and clinical pharmacology of efegatran (LY-294468): A novel antithrombin for the treatment of acute coronary syndromes. Clin Appl Thromb Hemost 1996, 2: 258-67.
19. Bagdy, D., Szabó, G., Barabás, É. et al. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost 1992, 68: 125-9.
20. Bozó, É., Boros, S., Kuszmann, J. et al. An economic synthesis of 1,2,3,4-tetra-O-acetyl-5-thio-D-xylopyranose and its transformation into 4-substituted-phenyl-1,5-dithio-β-D-xylopyranosides possessing antithrombotic activity. Carbohydr Res 1998, 308: 297-310.
21. Szabó G., Barabás É., Kuszmann J. et al. Thioglycosides as orally active antithrombotic agents. 14th Meet Int Soc Haematol (Stockholm) 1997, Abst P-370.
22. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl 2-deoxy-1,5-dithio-β-D-threo-pentopyranoside. Carbohydr Res 1997, 299: 59-67.
23. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-D-ribopyranosides as well as their 2-deoxy and 2,3-dideoxy derivatives possessing antithrombotic activity. Carbohydr Res 1999, 321: 52-66.
24. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl 2-azido-2-deoxy- and 3-azido-3-deoxy-1,5-dithio-β-D-xylopyranosides. Carbohydr Res 1997, 301: 23-32.
25. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl 4-azido-4-deoxy-1,5-dithio-β-D-xylopyranosides. Carbohydr Res 1997, 302: 149-62.
26. Overend, W.G., Stacey, M. The chemistry of the 2-desoxy-sugars. Adv Carbohydr Chem 1953, 8: 45-91.
27. Horowitz, J.P., Chua, J., Noel, M. Nucleosides V. The monomesylates of 1-(2′-deoxy-β-D-xylofuranosyl)thimine. J Org Chem 1964, 29: 2076-8.
28. Mitsuya, H., Weinhold, K.J., Furman, P.A. et al. 3′-Azido-3′-deoxythimidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985, 82: 7096-100.
29. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl 1,5-dithio-β-D-glucopyranoside and its 6-deoxy, as well as 6-deoxy-5-ene derivatives as oral antithrombotic agents. Carbohydr Res 1997, 304: 271-80.
30. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-L- and -D-arabinopyranosides possessing antithrombotic activity. Carbohydr Res 1998, 311: 191-202.
31. Bozó, É., Boros, S., Kuszmann, J. Synthesis of 4-cyanophenyl and 4-nitrophenyl 2,6-anhydro-1,2-dithio-D-manno-and altropyranosides as well as some of their derivatives possessing antithrombotic activity. Pol J Chem 1999, in press.
32. Davie, E.W., Fujikawa, K., Kisiel, W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991, 30: 10363-70.
33. Csomor, K., Kárpáti, E., Komlódi, J. et al. Oral antithrombotic activity of new thioglycosides in rat models of venous thrombosis. Haemostasis 1998, 28 (Suppl. 2): 463.
34. Sandset, P.M. The role of tissue factor pathway inhibitor as a physiological anticoagulant. 13th Meet Int Soc Haematol (Sept 3-8, Istanbul) 1995, Lectures 183-9.
35. Cella, G., Vertolli, U., Naso, A. et al. Tissue factor pathway inhibitor activity in uremic patients during hemodialysis. Thromb Res 1996, 6: 671-7.
36. Sandset, P.M., Abildgaard, U., Larsen, M.L. Heparin induces release of extrinsic coagulation pathway inhibitor. Thromb Res 1988, 50: 803-13.
37. Szabó, G., Barabás, É., Kedves, R. et al. Some new thioglycosides as orally active antithrombotic agents. Haemostasis 1998, 28 (Suppl. 2): 434.
38. Markwardt, F., Klöcking, H.P., Nowak, G. Antithrombin und antiplasminwirkung von 4-Amidinophenylbrenztraubensaure (APPA) in vivo. Thromb Haemorrh 1970, 24: 240-7.
39. Bagdy, D., Barabás, É., Szabó, G., Bajusz, S., Szél, E. In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H. Thromb Haemost 1992, 67: 357-65.